Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa

References

• National Kidney Foundation Web site. Available from http://www.kidney.org [Last accessed 9 Aug 2007]
   Google Scholar
• Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14:2919–25
   PubMed Web of Science ®Google Scholar
• Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94–111
   PubMed Web of Science ®Google Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658–66
   PubMed Web of Science ®Google Scholar
• Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825–30
   Google Scholar
• Epogen® (Epoetin alfa) [US prescribing information]. Thousand Oaks, CA; Amgen Inc., 2007. Available from http://www.amgen.com/pdfs/misc/epogen_pi.pdf [Last accessed 8 Jun 2007]
   Google Scholar
• Aranesp® (darbepoetin alfa) [US prescribing information]. Amgen Inc., 2007. Available from http://www.aranesp.com/professional/prescribing_information.jsp [Last accessed 8 Jun 2007]
   Google Scholar
• Macdougall IC. C.E.R.A. (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436–40
   PubMedGoogle Scholar
• Brandt M, Lanzendorfer M, Frische J. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006;21(Suppl 4):iv9
   Google Scholar
• Dougherty FC, Reigner B, Jordan P, et al. A continuous erythropoietin receptor activator (C.E.R.A.) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004;15(Suppl 3):iii57
   Google Scholar
• Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211–5
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Reigner B, Dougherty FC. Consistent pharmacokinetic properties of C.E.R.A (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Am J Kidney Dis 2006;47:A41
   Google Scholar
• Macdougall IC, Walker R, Provenzano R, et al., on behalf of the ARCTOS Study Investigators. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14–19, 2006; San Diego, CA, USA
   Google Scholar
• Canaud B, Braun J, Locatelli F. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Presented at the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; July 15–18, 2006. Glasgow, Scotland, UK [abstract SP425]
   Google Scholar
• Sulowicz W, Locatelli F, Balla J. Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Presented at the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; July 15–18, 2006; Glasgow, Scotland, UK [abstract SP424]
   Google Scholar
• Klinger M, Arias M, Vargemezis, et al., on behalf of the AMICUS Study Investigators. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14–19, 2006; San Diego, CA, USA
   Google Scholar
• Levin NW, Fishbane S, Cañedo FV, et al, on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). The Lancet 2007;370:1415–21.
   Google Scholar
• Levin NW, Imbasciati E, Combe C, et al., on behalf of the MAXIMA Study Investigators. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender, or diabetic status. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14–19, 2006; San Diego, CA, USA
   Google Scholar
• Sulowicz W, Locatelli F, Ryckelynck JP, et al., for the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637–46
   Google Scholar
• Ryckelynck J-P, Harris K, Selgas R, et al., on behalf of the PROTOS Study Investigators. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14–19, 2006; San Diego, CA, USA
   Google Scholar
• Brazeau GA, Cooper B, Svetic KA, et al. Current perspectives on pain upon injection of drugs. J Pharm Sci 1998;87:667–77
   PubMed Web of Science ®Google Scholar
• Frenken LA, van Lier HJ, Gerlag PG, et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ 1991;303:288
   PubMed Web of Science ®Google Scholar
• Lui SF, Leung CB, Li PK, et al. Pain after subcutaneous injection of erythropoietin. BMJ 1991;303:856
   PubMedGoogle Scholar
• Granolleras C, Leskopf W, Shaldon S, et al. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294–8
   PubMed Web of Science ®Google Scholar
• Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992;12:68–72
   Google Scholar
• Stevens JM, Auer J, Strong CA, et al. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991;6:487–94
   PubMed Web of Science ®Google Scholar
• Bommer J, Weinreich T, Ritz E, et al. Efficacy of subcutaneous or intravenous recombinant human erythropoietin therapy in dialysis patients. Nephrol Dial Transplant 1989;4:471 [abstract]
   Google Scholar
• Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41–4
   Google Scholar
• Yu AW, Leung CB, Li PK, et al. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int J Artif Organs 1998;21:341–3
   PubMed Web of Science ®Google Scholar
• Frenken LA, van Lier HJ, Jordans JG, et al. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 1993;22:553–6
   PubMed Web of Science ®Google Scholar
• Frenken LA, van Lier HJ, Koene RA. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa. Nephrol Dial Transplant 1994;9:1295–8
   PubMed Web of Science ®Google Scholar
• Morris KP, Hughes C, Hardy SP, et al. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help? Nephrol Dial Transplant 1994;9:1299–301
   PubMed Web of Science ®Google Scholar
• Cummings EA, Reid GJ, Finley GA, et al. Prevalence and source of pain in pediatric inpatients. Pain 1996;68:25–31
   PubMed Web of Science ®Google Scholar
• Schaeffer F. Increased subcutaneous injection pain with darbepoetin alfa compared with epoetin beta in children: results of a randomized, double-blind study. Poster presented at the American Society of Nephrology (ASN) Renal Week; October 29–November 4, 2004; St. Louis, Missouri, USA
   Google Scholar
• Geary DF, Keating LE, Vigneux A, et al. Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 2005;68:1759–65
   PubMed Web of Science ®Google Scholar
• Schmitt CP, Nau B, Brummer C, et al. Increased injection pain with darbepoetin alfa compared to epoetin-beta in paediatric dialysis patients. Nephrol Dial Transplant 2006;21:3520–4
   PubMed Web of Science ®Google Scholar
• Choukroun G, Gelu-Mantoulet S, Rouanet S, et al. Pain at the injection site: results of the first cross-over study comparing epoetin beta and darbepoetin alfa administered subcutaneously in healthy volunteers. Presented at the European Renal Association-European Dialysis and Transplantation Association (KLII ERA-EDTA) Congress; June 4–7, 2005; Istanbul, Turkey [abstract MP187]
   Google Scholar
• SmPC Aranesp® (darbepoetin alfa). For injection. February 28, 2006. Available from http://www.emea.europa.eu/humandocs/Humans/EPAR/aranesp/aranesp.htm [Last accessed 12 Oct 2007]
   Google Scholar
• Machin D, Lewith GT, Wylson S. Pain measurement in randomized clinical trials. A comparison of two pain scales. Clin J Pain 1988;4:161–8
   Google Scholar